Whalesbook
📉 The Financial Deep Dive
Jubilant Pharmova Limited's un-audited financial results for the quarter and nine months ended December 31, 2025, reveal a stark divergence between revenue growth and profitability, primarily due to significant exceptional items.
Consolidated Performance:
For the third quarter of fiscal year 2026 (Q3 FY26), the company posted a consolidated revenue of ₹21,225 Cr, marking a robust 16.5% increase year-over-year. However, this top-line growth did not translate to the bottom line. Profit Before Tax (PBT) experienced a steep 50.9% decline to ₹934 Cr, while Net Profit plummeted by 53.5% year-over-year to ₹558 Cr. This significant drop was substantially influenced by ₹397 Cr in exceptional expenses incurred during the quarter.
These exceptional items cast a long shadow over the nine-month period (9M FY26) as well. Consolidated revenue grew 12.2% YoY to ₹59,528 Cr. However, net profit saw a dramatic 70.2% plunge to ₹1,305 Cr. The nine-month exceptional items included a gain on the sale of certain assets (+₹217 Cr), significant expenses related to the temporary suspension of manufacturing operations at the Montreal, Canada facility for remediation (-₹443 Cr), and amortization of debt initiation costs (-₹96 Cr).
Standalone Performance:
On a standalone basis, revenue from operations for Q3 FY26 surged 20% YoY to ₹673 Cr. The company reported a net profit of ₹66 Cr for continuing operations, a substantial turnaround from a loss of ₹480 Cr in the prior year's comparable quarter. This improvement is partly due to the sale of the Active Pharmaceutical Ingredients (API) business on September 1, 2025, which is now classified under 'Discontinued Operations'. Including discontinued operations, the reported net profit for Q3 FY26 was ₹66 Cr, a significant recovery from a net loss of ₹64 Cr in Q3 FY25.
However, the nine months ended December 31, 2025, present a different picture for standalone continuing operations, which reported a loss of ₹373 Cr, compared to a profit of ₹213 Cr in the prior year. The total standalone net profit for the nine months stood at ₹60 Cr, a marginal increase from ₹56 Cr in the previous year.
The Grill & Red Flags:
The sharp decline in consolidated net profit, driven by exceptional expenses related to the Montreal facility's remediation, is a key concern. Investors will scrutinize the operational impact and cost associated with this event. The deterioration in standalone net profit for continuing operations also warrants attention. Notably, the management did not provide any forward-looking guidance in this announcement, adding an element of uncertainty.
Financial Deep Dive:
- Margins: Consolidated EBITDA margins were not explicitly provided but implied to be under pressure due to exceptional costs. Standalone reported net profit turned positive, but continuing operations showed a loss.
- Exceptional Items: The impact of ₹397 Cr in consolidated exceptional expenses for Q3 FY26 and a net effect of exceptional items in 9M FY26 are critical factors affecting reported profitability.
Risks & Outlook:
Key risks include the ongoing assessment of the impact of new Labour Codes and potential operational disruptions or further costs associated with the Montreal facility. The company is exploring the utilization of Minimum Alternate Tax (MAT) credit under a proposed Finance Bill. The absence of management guidance leaves the Street to assess future performance based on operational trends and market conditions.